Changeable conditional survival rates and associated prognosticators in patients with metastatic renal cell carcinoma receiving first-line targeted therapy

This study aimed to evaluate conditional survival (CS) probabilities in patients with metastatic renal cell carcinoma (mRCC) who undergo first-line tyrosine kinase inhibitor (TKI) therapy and identify the predictors for CS over time.

Source: The Journal of Urology - June 22, 2018 Category: Urology & Nephrology Authors: Minyong Kang, Jae Young Park, Chang Wook Jeong, Eu Chang Hwang, Cheryn Song, Sung-Hoo Hong, Cheol Kwak, Jinsoo Chung, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Se Hoon Park, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Seong Il Seo Source Type: research